The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Nivolumab Shows Promise Versus Docetaxel for NSCLC in Checkmate 057 Trial

David Carbone, MD, PhD
Published Online: 10:58 PM, Fri June 5, 2015

David Carbone, MD, PhD, professor, internal medicine, College of Medicine Director, James Thoracic Center, James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center discusses the Checkmate 057 trial, which evaluates Opdivo (nivolumab) versus docetaxel in previously treated patients with advanced non-squamous non-small cell lung cancer (NSCLC).

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.